By Rishika Sadam and Kashish Tandon Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg ...

By Rishika Sadam Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per ...

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

By Rishika Sadam Dec 12 (Reuters) - Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

There is more to this news than meets the eye.

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.

We recently published 13 Best ADR Stocks to Invest In. Novo Nordisk A/S (NYSE:NVO) is one of the best ADR stocks. Healthcare ...

The launch comes amid the company’s legal battle with Indian drugmakers, including Dr Reddy’s Laboratories and Sun Pharma, ...

An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s ...